USA – IDRx, Inc., a Plymouth, MA-based clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, raised $122m in Series A financing.
The round was led by Andreessen Horowitz and Casdin Capital, with participation from Nextech Invest, Forge Life Science Partners and other undisclosed investors. Led by Ben Auspitz, co-founder and CEO, IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision combination therapies. Its pipeline programs include small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRX-42 and IDRX-73 were acquired through license agreements with Merck KGaA, Darmstadt, Germany, and Blueprint Medicines, respectively. A Phase 1 first-in-human study of IDRX-42 has been initiated, and IDRX-73 is currently advancing towards the clinic. IDRX-42 was also recently granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of GIST. 02/08/2022
